Teleflex Incorporated (NYSE:TFX) Shares Sold by Tredje AP fonden

Tredje AP fonden cut its holdings in shares of Teleflex Incorporated (NYSE:TFX) by 50.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,663 shares of the medical technology company’s stock after selling 3,662 shares during the period. Tredje AP fonden’s holdings in Teleflex were worth $652,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of TFX. Apollon Wealth Management LLC increased its stake in Teleflex by 3.7% during the third quarter. Apollon Wealth Management LLC now owns 1,524 shares of the medical technology company’s stock worth $377,000 after purchasing an additional 55 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its stake in Teleflex by 2.5% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 102,909 shares of the medical technology company’s stock worth $25,451,000 after purchasing an additional 2,545 shares during the period. Victory Capital Management Inc. increased its stake in Teleflex by 364.6% during the third quarter. Victory Capital Management Inc. now owns 35,370 shares of the medical technology company’s stock worth $8,748,000 after purchasing an additional 27,757 shares during the period. KBC Group NV increased its stake in Teleflex by 13.2% during the third quarter. KBC Group NV now owns 4,577 shares of the medical technology company’s stock worth $1,132,000 after purchasing an additional 535 shares during the period. Finally, Huntington National Bank increased its stake in Teleflex by 32.5% during the third quarter. Huntington National Bank now owns 310 shares of the medical technology company’s stock worth $77,000 after purchasing an additional 76 shares during the period. 95.62% of the stock is currently owned by hedge funds and other institutional investors.

Teleflex Price Performance

TFX stock opened at $137.79 on Friday. The company has a market capitalization of $6.39 billion, a P/E ratio of 27.39, a PEG ratio of 1.73 and a beta of 1.21. Teleflex Incorporated has a twelve month low of $128.55 and a twelve month high of $249.90. The business has a 50 day simple moving average of $166.99 and a 200-day simple moving average of $197.69. The company has a current ratio of 2.42, a quick ratio of 1.39 and a debt-to-equity ratio of 0.37.

Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, February 27th. The medical technology company reported $3.89 earnings per share for the quarter, beating the consensus estimate of $3.86 by $0.03. The business had revenue of $795.40 million during the quarter, compared to the consensus estimate of $813.24 million. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. As a group, equities analysts anticipate that Teleflex Incorporated will post 13.98 EPS for the current year.

Teleflex Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 17th. Investors of record on Friday, March 7th will be given a $0.34 dividend. The ex-dividend date of this dividend is Friday, March 7th. This represents a $1.36 dividend on an annualized basis and a yield of 0.99%. Teleflex’s dividend payout ratio (DPR) is 95.77%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on TFX. Piper Sandler reiterated a “neutral” rating and set a $140.00 price target (down from $255.00) on shares of Teleflex in a research note on Friday, February 28th. Wells Fargo & Company cut their target price on shares of Teleflex from $214.00 to $146.00 and set an “equal weight” rating on the stock in a research note on Friday, February 28th. Truist Financial cut their target price on shares of Teleflex from $200.00 to $149.00 and set a “hold” rating on the stock in a research note on Monday, March 3rd. StockNews.com lowered shares of Teleflex from a “buy” rating to a “hold” rating in a research note on Friday, February 28th. Finally, Citizens Jmp lowered shares of Teleflex from an “outperform” rating to a “market perform” rating in a research note on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $182.63.

Teleflex Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.